Skip to main content
. 2020 Mar 2;12(4):e11177. doi: 10.15252/emmm.201911177

Figure 1. Cisplatin treatment leads to EphA2 upregulation in ex vivo HGSC cultures.

Figure 1

  • A
    Confocal micrographs show cytokeratin 7 (CK7, green) and vimentin (red) in patient‐derived HGSC cells cultured in 3D collagen for 7 days. Scale bars: 50 μm.
  • B
    Confocal micrographs of EphA2 (red) in HGSC cells cultured in 3D collagen for 7 days and treated for 72 h with 10 μM cisplatin (5 μM for OCKI_p01). The intensity of EphA2 is comparable only between mock and treatment conditions for each patient. Scale bars: 20 μm.
  • C
    Chart illustrates EphA2 fold change after treatment. Mock is set to one. N = 3.
Data information: In (C), data are presented as mean fold change (SD). **P < 0.01. Exact P‐values are provided in Appendix Table S10, Student's t‐test.